Table 2.
Changes in clinical parameters during the observation period.
| AFTER THE INITIATION OF ORAL FEBUXOSTAT TREATMENT | P VALUE | |||||||
|---|---|---|---|---|---|---|---|---|
| BASELINE | 1 MONTH | 2 MONTHS | 3 MONTHS | 4 MONTHS | 5 MONTHS | 6 MONTHS | ||
| Systolic BP (mmHg) | 141 ± 20 | 137 ± 16 | 141 ± 29 | 141 ± 16 | 142 ± 21 | 148 ± 21* | 149 ± 19* | <0.001 |
| Diastolic BP (mmHg) | 74 ± 11 | 73 ± 9 | 73 ± 10 | 76 ± 10 | 76 ± 12 | 74 ± 11 | 73 ± 11 | 0.186 |
| Hb (g/dL) | 10.7 ± 1.0 | 10.8 ± 1.0 | 10.9 ± 1.1 | 10.8 ± 1.6 | 10.9 ± 1.3 | 10.9 ± 1.3 | 10.6 ± 1.0 | 0.989 |
| Hct (%) | 33.9 ± 3.1 | 33.9 ± 3.2 | 33.5 ± 3.4 | 34.1 ± 3.4 | 34.0 ± 4.3 | 34.0 ± 3.6 | 33.1 ± 2.9 | 0.976 |
| Plt (×104/μl) | 16.8 (IR: 14.2–22.7) | 15.6 (IR: 13.6–25.1) | 17.8 (IR: 14.2–24.6) | 18.4 (IR: 14.9–25.2) | 17.7 (IR: 12.8–23.1) | 16.7 (IR: 12.8–21.6) | 18.3 (IR: 11.7–21.8) | 0.887 |
| BUN (mg/dL) | 62.1 ± 11.7 | 64.8 ± 18.6 | 65.1 ± 15.8 | 63.2 ± 14.1 | 64.7 ± 19.1 | 67.0 ± 21.4 | 69.9 ± 16.5 | 0.886 |
| Cr (mg/dL) | 11.4 ± 1.9 | 11.8 ± 2.0 | 11.8 ± 1.9 | 11.8 ± 2.3 | 11.9 ± 2.2 | 11.5 ± 2.2 | 11.5 ± 2.2 | 0.991 |
| Na (mmol/l) | 138 ± 4 | 139 ± 4 | 140 ± 4 | 139 ± 4 | 139 ± 4 | 139 ± 3 | 138 ± 2 | 0.805 |
| K (mmol/l) | 4.9 ± 0.9 | 4.9 ± 0.8 | 5.0 ± 1.0 | 5.0 ± 0.9 | 4.9 ± 0.7 | 5.0 ± 0.8 | 5.0 ± 0.9 | 0.999 |
| CI (mmol/l) | 102 ± 5 | 103 ± 4 | 103 ± 4 | 103 ± 4 | 103 ± 5 | 102 ± 4 | 103 ± 3 | 0.93 |
| Ca (mg/dL) | 8.8 ± 0.8 | 9.0 ± 0.9 | 8.8 ± 0.6 | 8.8 ± 0.6 | 8.9 ± 0.7 | 9.1 ± 0.8 | 9.0 ± 0.9 | 0.852 |
| Pi (mg/dL) | 4.5 ± 1.3 | 5.1 ± 1.2 | 5.3 ± 1.4 | 5.0 ± 0.9 | 5.1 ± 1.5 | 5.6 ± 1.5 | 4.9 ± 1.0 | 0.296 |
| AST (U/l) | 16.5 ± 15.8 | 18.0 ± 15.4 | 15.0 ± 6.7 | 15.0 ± 6.4 | 17.2 ± 7.5 | 18.4 ± 8.4 | 18.3 ± 13.6 | 0.938 |
| ALT (U/l) | 17.9 ± 17.6 | 18.8 ± 16.7 | 15.2 ± 9.4 | 14.4 ± 8.3 | 14.0 ± 8.0 | 17.5 ± 10.4 | 19.4 ± 18.2 | 0.857 |
| LDH (U/l) | 179 ± 40 | 189 ± 39 | 179 ± 28 | 178 ± 26 | 180 ± 30 | 191 ± 45 | 188 ± 48 | 0.923 |
Note:
*
P < 0.05 versus baseline.